Recombinant Human PGP9.5 Protein (His tag)

Beta LifeScience SKU/CAT #: BLA-6917P

Recombinant Human PGP9.5 Protein (His tag)

Beta LifeScience SKU/CAT #: BLA-6917P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Host Species Human
Accession P09936
Synonym Epididymis luminal protein 117 Epididymis secretory protein Li 53 HEL 117 HEL S 53 NDGOA Neuron cytoplasmic protein 9.5 OTTHUMP00000218137 OTTHUMP00000218139 OTTHUMP00000218140 OTTHUMP00000218141 Park 5 PARK5 PGP 9.5 PGP9.5 PGP95 Protein gene product 9.5 Ubiquitin C terminal esterase L1 Ubiquitin C terminal hydrolase Ubiquitin C terminal hydrolase L1 Ubiquitin carboxyl terminal esterase L1 Ubiquitin carboxyl terminal hydrolase isozyme L1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Ubiquitin thioesterase L1 Ubiquitin thiolesterase Ubiquitin thiolesterase L1 UCH-L1 UCHL1 UCHL1_HUMAN
Description Recombinant Human PGP9.5 Protein (His tag) was expressed in E.coli. It is a Full length protein
Source E.coli
Molecular Weight 26 kDa including tags
Purity >92% SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Formulation Lyophilised
Stability The recombinant protein samples are stable for up to 12 months at -80°C
Reconstitution See related COA
Unit Definition For Research Use Only
Storage Buffer Shipped at 4°C. Store at -80°C. Avoid freeze / thaw cycle.

Target Details

Target Function Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity.
Subcellular Location Cytoplasm. Endoplasmic reticulum membrane; Lipid-anchor. Note=About 30% of total UCHL1 is associated with membranes in brain.
Protein Families Peptidase C12 family
Database References
Associated Diseases Parkinson disease 5 (PARK5); Spastic paraplegia 79, autosomal recessive (SPG79)
Tissue Specificity Found in neuronal cell bodies and processes throughout the neocortex (at protein level). Expressed in neurons and cells of the diffuse neuroendocrine system and their tumors. Weakly expressed in ovary. Down-regulated in brains from Parkinson disease and A

Gene Functions References

  1. The proteins UCH-L1 and alpha-internexin could be independent prognostic biomarkers of pancreatic neuroendocrine tumors. PMID: 28526880
  2. We have also demonstrated that UCHL1 S-nitrosylation provides seeding for faster aggregation of a-synuclein. Finally, the in vitro nitrosylation of UCHL1 was corroborated with rotenone induced mouse model of PD PMID: 28300150
  3. In newborns undergoing cardiac surgery, ubiquitin C-terminal hydrolase 1 showed a significant rise at 0 hours in the deep hypothermic circulatory arrest group compared to baseline. Levels returned to baseline at 12 hours. There was an early rise in UCHL1 at 0 hours in the cardiopulmonary bypass group. PMID: 29945509
  4. Overexpression of UCHL1 genes promoted apoptosis in cells treated with VER+ADM. UCHL1 knockdown using siRNA weakened the effect of ADM+VER, indicating that ADM+VER promotes HCC cell apoptosis and that UCHL1 genes participate in VER-mediated promotion in tumor cell apoptosis. PMID: 29627846
  5. Cholangiocarcinoma patients who had high methylation of HTATIP2 and low methylation of UCHL1 showed longer overall survival than those with low HTATIP2 methylation and high UCHL1 methylation. PMID: 29359783
  6. High UCHL1 expression is associated with posterior longitudinal ligament ossification. PMID: 29782494
  7. Prx II exhibited more effective molecular chaperone activity than Prx I when UCH-L1 was the client. Prx II interacted with UCH-L1 through its C-terminal region to protect UCH-L1 from thermal or oxidative inactivation PMID: 29339092
  8. Data report that the expression of UCH-L1 is significantly higher in breast cancer cells with higher invasive ability. Also, the overexpression of UCH-L1 led to activation of Akt and phosphorylation. Thus, these findings demonstrated that UCH-L1 promotes invasion of breast cancer cells. PMID: 28636190
  9. The authors observed higher serum levels of GFAP and UCH-L1 in brain-injured children compared with controls and also demonstrated a step-wise increase of biomarker concentrations over the continuum of severity from mild to severe traumatic brain injury. Serum UCH-L1 and GFAP concentrations also strongly predicted poor outcome. PMID: 27319802
  10. UCHL1 inhibits autophagy and is depending on its de-ubiquitinating activity. PMID: 29462615
  11. Uchl1 concentrations in the blood plasma of boys with cryptorchidism, may reflect the heat-induced apoptosis of germ cells PMID: 29401475
  12. Overexpression of UCHL1 is associated with thermal injury. PMID: 28193576
  13. UCHL1 localizes to TTAGGG repeats at telomeres and interstitial telomeric sequences. A weak or transient interaction between UCHL1 and the shelterin complex was confirmed by immunoprecipitation and proximity ligation assays. PMID: 29126443
  14. novel biomarker for identifying malignant potential of primary well-differentiated and moderately differentiated pancreatic neuroendocrine tumors PMID: 29150024
  15. detection of significantly higher levels of UCH-L1 in patients with ischemic stroke and intracranial hemorrhage compared to patients with metabolic disorder induced impaired consciousness and healthy volunteers PMID: 28651886
  16. This study also showed that UCH-L1 promotes angiogenesis of HUVECs, as well as invasion in cancer cells, by up-regulating ROS by deubiquitination of NOX4, suggesting that UCH-L1 plays a key role in angiogenesis of HUVECS by regulating ROS levels by deubiquitination of NOX4. PMID: 29128359
  17. Familial mutations and post-translational modifications of UCH-L1 in Parkinson's disease have been summarized. (Review) PMID: 26899237
  18. Aberrant expression of UCHL1 in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/Beta catenin activity PMID: 28472177
  19. Suppression of MITF activity by UCHL1 via protein degradation might aid in the development of new therapeutic approaches for melanoma or dyspigmentation disorders. PMID: 28392346
  20. Overexpression of UCH-L1 in MCF7 cells up-regulated MDR1, CD147, MMP2, and MMP9, which conferred multidrug resistance and promoted migration/invasion. PMID: 26293643
  21. Folding of a 52-Knotted Protein PMID: 28002735
  22. This study demonstrated that UCH-L1 was detectible within 1 hour of injury and rose rapidly and peaked at 8 hours after injury and declined rapidly over 48 hours. PMID: 27018834
  23. This study establishes the importance of UCHL1 in neurodegeneration, provides new mechanistic insight about ubiquitin processing, and underlines the complexity of the different roles of UCHL1 PMID: 28007905
  24. TGF-beta1 can promote PGP9.5 expression in Cancer associated fibroblasts to facilitate the growth of cancer cells. PMID: 27840994
  25. PGP9.5 is also expressed in benign fibroblastic lesions PMID: 27914685
  26. cytoplasmic accumulation of P53 was strongly associated with the unmethylated UCHL1 profile (P = 0.006), supporting the relationship between these two proteins in sporadic colorectal cancer PMID: 26314856
  27. indicated that the LDT is an accurate, robust and automated assay, which adequately and reliably identifies patients presenting with small fiber neuropathy, and therefore has potential for use in large scale clinical studies PMID: 27215701
  28. No difference in cord blood concentration found between hypoxic-ischemic encephalopathy neonates and controls PMID: 26135781
  29. UCHL1 has a role in Alzheimer Disease [review] PMID: 26881020
  30. UCHL1 expression is highly upregulated upon hepatic stellate cell (HSC) activation and is involved in the regulation of HSC proliferation PMID: 26264933
  31. UCH-L1 is a promising prognostic biomarker for GCAs and might play an important role in the carcinogenesis of gastric cancer. PMID: 26823707
  32. Folloing aneurysmal subarachnoid hemorrhage, eleevated UCH-L1 levels during the five-day follow-up were associated with unfavorable neurological outcome. PMID: 26810533
  33. UCH-L1 plays a crucial role in modulating the degradation of EGFR and promoting malignant properties in multi-drug resistant breast cancer PMID: 26722437
  34. High UCHL1 expression is associated with multiple myeloma. PMID: 26513019
  35. The neuronal marker UCH-L1 is induced in, and specifically augments the oncogene-induced transformation of, germinal center B cells. PMID: 26702068
  36. The promoter methylation degree of FLNC, THBS1, UCHL1, and DLEC1 in serum could tell the existence of GC and only UCHL1 in the serum was also associated with poor prognosis of GC. PMID: 26550574
  37. The results of this study suggest the role for UCHL1 in promoting Corticospinal motor neurons health and stability. PMID: 25596590
  38. UCH-L1 is significantly associated with outcome, but it does not add predictive power to commonly used prognostic variables in a population of patients with TBI of varying severities. PMID: 26547005
  39. Serum UCH-l1 levels serve as a novel biomarker for neuronal damage from white matter lesions. PMID: 26232084
  40. High Ubiquitin C-terminal hydrolase-L1 increases cancer cell invasion by modulating hydrogen peroxide generated via NADPH oxidase 4. PMID: 25915537
  41. These findings demonstrated that UCHL1 promoted cell proliferation, migration, and invasion depending on its de-ubiquitinase activity by activating Akt and Erk1/2 pathways PMID: 26018507
  42. These results suggest that ubiquitin C-terminal hydrolase and alphaII-spectrin breakdown product 145 kDa may be useful in assessing outcome after pediatric traumatic brain injury. PMID: 22022780
  43. Pathogenetic tau truncation may contribute to synaptic deterioration in Alzheimer disease by aberrant recruitment of Parkin and UCHL-1 to mitochondria. PMID: 25687137
  44. UCHL1 promotes metastases as a deubiquitinating enzyme for HIF-1alpha. PMID: 25615526
  45. Meta-analysis suggesting that UCHL1 S18Y polymorphism is moderately associated with susceptibility to Parkinson's disease PMID: 25370916
  46. Potential of UCHL1 as biomarker for destruction of pancreatic beta cells. PMID: 25638021
  47. Data identified a variant of UCH-L1 lacking N-terminal 11 amino acids designated as NT-UCH-L1 and was found to have a protective role in the Parkinson's disease model in vitro and in vivo. PMID: 24959670
  48. UCHL1 may delay Alzheimer's progression by regulating APP degradation. PMID: 25466238
  49. miR-922 increasing the levels of phosphorylated tau by regulating UCHL1 levels contributed to the pathogenesis of Alzheimer diseases. PMID: 24950120
  50. Skin PGP 9.5 expression, a neuronal marker, was significantly lower in patients with familial transthyretin amyloid neuropathy compared to controls. PMID: 25973863


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed